IR@PKUHSC  > 北京大学第一临床医学院  > 消化科
学科主题临床医学
Head-to-head comparison of H-2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis
Wang, Wei-Hong1,2; Huang, Jia-Qing2,3; Zheng, Ge-Fan2; Xia, Harry Hua-Xiang2; Wong, Wai-Man2; Lam, Shiu-Kum2; Wong, Benjamin Chun-Yu2
关键词Erosive esophagitis H-2-receptor antagonists Proton pump inhibitors Meta-analysis
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2005-07-14
11期:26页:4067-4077
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
资助者University of Hong Kong, Hong Kong, China ; University of Hong Kong, Hong Kong, China
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]GASTROESOPHAGEAL-REFLUX DISEASE ; SHORT-TERM TREATMENT ; 300 MG RANITIDINE ; HELICOBACTER-PYLORI INFECTION ; RANDOMIZED CONTROLLED-TRIAL ; GASTRIC-ACID-SECRETION ; HIGH-DOSE RANITIDINE ; OMEPRAZOLE 40 MG ; DOUBLE-BLIND ; MULTICENTER TRIAL
英文摘要

AIM: To systematically evaluate the efficacy of H-2-receptor antagonists (H2RAs) and proton pump inhibitors in healing erosive esophagitis (EE).

METHODS: A meta-analysis was performed. A literature search was conducted in PubMed, Medline, Embase, and Cochrane databases to include randomized controlled head-to-head comparative trials evaluating the efficacy of H2RAs or proton pump inhibitors in healing EE. Relative risk (RR) and 95% confidence interval (CI) were calculated under a random-effects model.

RESULTS: RRs of cumulative healing rates for each comparison at 8 wk were: high dose vs standard dose H2RAs, 1.17 (95% CI, 1.02-1.33); standard dose proton pump inhibitors vs standard dose H2RAs, 1.59 (95% CI, 1.44-1.75); standard dose other proton pump inhibitors vs standard dose omeprazole, 1.06 (95% CI, 0.98-1.06). Proton pump inhibitors produced consistently greater healing rates than H2RAs of all doses across all grades of esophagitis, including patients refractory to H2RAs. Healing rates achieved with standard dose omeprazole were similar to those with other proton pump inhibitors in all grades of esophagitis.

CONCLUSION: H2RAs are less effective for treating patients with erosive esophagitis, especially in those with severe forms of esophagitis. Standard dose proton pump inhibitors are significantly more effective than H2RAs in healing esophagitis of all grades. Proton pump inhibitors given at the recommended dose are equally effective for healing esophagitis. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.

语种英语
资助者University of Hong Kong, Hong Kong, China ; University of Hong Kong, Hong Kong, China
WOS记录号WOS:000208317700016
引用统计
被引频次:19[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67667
专题北京大学第一临床医学院_消化科
作者单位1.Peking Univ, Hosp 1, Dept Gastroenterol, Beijing 100871, Peoples R China
2.Univ Hong Kong, Dept Med, Fac Med, Hong Kong, Hong Kong, Peoples R China
3.Univ Hong Kong, Clin Trials Ctr, Fac Med, Hong Kong, Hong Kong, Peoples R China
推荐引用方式
GB/T 7714
Wang, Wei-Hong,Huang, Jia-Qing,Zheng, Ge-Fan,et al. Head-to-head comparison of H-2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2005,11(26):4067-4077.
APA Wang, Wei-Hong.,Huang, Jia-Qing.,Zheng, Ge-Fan.,Xia, Harry Hua-Xiang.,Wong, Wai-Man.,...&Wong, Benjamin Chun-Yu.(2005).Head-to-head comparison of H-2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis.WORLD JOURNAL OF GASTROENTEROLOGY,11(26),4067-4077.
MLA Wang, Wei-Hong,et al."Head-to-head comparison of H-2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis".WORLD JOURNAL OF GASTROENTEROLOGY 11.26(2005):4067-4077.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Wei-Hong]的文章
[Huang, Jia-Qing]的文章
[Zheng, Ge-Fan]的文章
百度学术
百度学术中相似的文章
[Wang, Wei-Hong]的文章
[Huang, Jia-Qing]的文章
[Zheng, Ge-Fan]的文章
必应学术
必应学术中相似的文章
[Wang, Wei-Hong]的文章
[Huang, Jia-Qing]的文章
[Zheng, Ge-Fan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。